Merck & Co., Inc. (MRK) EBITDA Margin: 45.17%
Is Merck & Co., Inc.’s EBITDA margin high or low?
Merck & Co., Inc.'s EBITDA margin of 45.17% is 40% above its 5-year average of 32.32%, near the high end of its 5-year range (11.49%–45.17%).
The EBITDA margin for Merck & Co., Inc. (MRK) is 45.17% as of Wednesday, June 10, 2026. It is above its 12-month average by 6.00% (42.62%).
MRK EBITDA Margin Chart
MRK Average EBITDA Margin Chart
MRK Current vs Average EBITDA Margin Chart
MRK EBITDA Margin Metrics
EBITDA MARGIN
45.17%
EBITDA MARGIN AVG TTM
42.62%
EBITDA MARGIN AVG 3Y
33.17%
EBITDA MARGIN AVG 5Y
32.32%
EBITDA MARGIN AVG 10Y
31.33%
EBITDA MARGIN AVG 15Y
32.59%
EBITDA MARGIN AVG 20Y
34.76%
CURRENT VS TTM AVG
+6.00%
CURRENT VS 3Y AVG
+36.19%
CURRENT VS 5Y AVG
+39.74%
CURRENT VS 10Y AVG
+44.19%
CURRENT VS 15Y AVG
+38.59%
CURRENT VS 20Y AVG
+29.95%
MRK Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $293.02B | 45.17% | 42.62% | 33.17% | 32.32% |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 5.15% | 6.08% | 7.94% | 8.50% |
| AbbVie Inc. (ABBV) | $399.54B | 28.82% | 27.64% | 32.13% | 33.01% |
| Amgen Inc. (AMGN) | $183.75B | 43.12% | 41.54% | 45.45% | 46.07% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 25.73% | 26.63% | 26.49% | 27.97% |
| Abbott Laboratories (ABT) | $154.66B | 26.06% | 25.95% | 26.39% | 26.63% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 46.12% | 30.77% | 33.17% | 31.82% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 35.99% | 34.83% | 32.83% | 33.18% |
| Pfizer Inc. (PFE) | $146.36B | 24.12% | 26.30% | 27.39% | 29.84% |
| Danaher Corporation (DHR) | $130.25B | 28.27% | 29.38% | 31.44% | 31.51% |
Margin Comparison
Gross Margin
75.9%
EBITDA Margin
45.2%
Operating Margin
27.6%
Net Margin
13.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Merck & Co., Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Merck & Co., Inc. (MRK)?
- The EBITDA margin for MRK stock is 45.17%.
- Is Merck & Co., Inc.'s EBITDA margin high or low?
- Merck & Co., Inc.'s EBITDA margin of 45.17% is 40% above its 5-year average of 32.32%, near the high end of its 5-year range (11.49%–45.17%).
- What is the TTM average EBITDA margin for Merck & Co., Inc. (MRK)?
- The TTM average EBITDA margin for MRK stock is 42.62%.
- What is the 3Y average EBITDA margin for Merck & Co., Inc. (MRK)?
- The 3Y average EBITDA margin for MRK stock is 33.17%.
- What is the 5Y average EBITDA margin for Merck & Co., Inc. (MRK)?
- The 5Y average EBITDA margin for MRK stock is 32.32%.
- What is the 10Y average EBITDA margin for Merck & Co., Inc. (MRK)?
- The 10Y average EBITDA margin for MRK stock is 31.33%.
- What is the 15Y average EBITDA margin for Merck & Co., Inc. (MRK)?
- The 15Y average EBITDA margin for MRK stock is 32.59%.
- What is the 20Y average EBITDA margin for Merck & Co., Inc. (MRK)?
- The 20Y average EBITDA margin for MRK stock is 34.76%.
Merck & Co., Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 45.17% |
| 2024-12-31 | 40.06% |
| 2023-12-31 | 11.49% |
| 2022-12-31 | 35.95% |
| 2021-12-31 | 36.75% |
| 2020-12-31 | 24.52% |
| 2019-12-31 | 29.07% |
| 2018-12-31 | 33.08% |
| 2017-12-31 | 29.79% |
| 2016-12-31 | 27.19% |
| 2015-12-31 | 31.52% |
| 2014-12-31 | 58.49% |
| 2013-12-31 | 30.28% |
| 2012-12-31 | 34.76% |
| 2011-12-31 | 32.17% |
| 2010-12-31 | 21.20% |
| 2009-12-31 | 66.81% |
| 2008-12-31 | 49.53% |
| 2007-12-31 | 31.43% |
| 2006-12-31 | 26.31% |
| 2005-12-31 | 34.38% |
| 2004-12-31 | 35.73% |
| 2003-12-31 | 43.95% |
| 2002-12-31 | 48.12% |
| 2001-12-31 | 49.11% |
| 2000-12-31 | 26.47% |
| 1999-12-31 | 27.68% |
| 1998-12-31 | 27.48% |
| 1997-12-31 | 28.35% |
| 1996-12-31 | 29.81% |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis